From the world of health-care stocks, Calgary-based Voyageur Pharmaceuticals Ltd. (TSX-Venture:VM) told investors has signed an Letter of Intent with an established international mining company (only identified as the “Counterparty”), which has developed a low cost method to extract the natural occurring carbon molecule, C-60 to C-90, from large natural-occurring fullerene resources.
The technology to extract C-60 from natural fullerene deposits is ground-breaking and a first in this industry.
According to Voyageur CEO Brent Willis, “Voyageur will be the first company to be able to mass produce C-60 at a low cost, allowing for multiple drug products to be developed.
“The barriers for C-60 based drugs has now been broken, which opens up the industry to develop new effective drugs and health care products on an economic scale.”
The API, C-60, is a natural, highly effective super antioxidant, like more common antioxidants (Vitamin C, Vitamin A and Selenium). It scavenges toxic free radicals but it stands out as a notable anti-aging innovation because it selectively scavenges the reactive oxygen species that do the most damage to humans as opposed to just working by osmosis like a normal antioxidant.
VM shares veered into Monday’s final hour of trade, with a jump of 1.5 cents, or 25%, to 7.5 cents, on volume of 144,000 shares.
